Pseudoprogression versus true progression in glioblastoma patients : A multiapproach analysis
PO-1522
Abstract
Pseudoprogression versus true progression in glioblastoma patients : A multiapproach analysis
Authors: Anne Laprie1, Ingrid SIDIBE2
1Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse – Oncopôle, radiation Oncology, Toulouse, France; 21Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse – Oncopôle, , radiation Oncology, Toulouse, France
Show Affiliations
Hide Affiliations
Purpose or Objective
Differentiating early tumor progression (ETP) from
pseudoprogression (PSP) in patients with glioblastoma (GBM) is crucial to
improve prognosis. Objective of this study was to investigate the ability of
multiapproach analysis including clinical data, diffusion weighted imaging
(DWI), perfusion magnetic resonance imaging (MRI) and 3D magnetic resonance spectroscopic imaging
(MRSI) to distinguish ETP from PSP in patients with GBM.
Material and Methods
Among
180 patients included in prospective phase III Randomized SPECTROGLIO trial
(NCT01507506)(1), 46
patients were suspected with progression within 6 months after end of
radiotherapy. Ratios of choline/creatine (Cho/Cr), choline/N-acetyl aspartate
(Cho/NAA) and lactate/N-acetyl aspartate (Lac/NAA) were extracted after
co-registration of 3D-MRSI with the FLAIR and T1-weighted
images before and after gadolinium
administration. Voxels were analysed according to the region to which they belonged: contrast-enhanced
(CE) lesion, necrosis and infiltrative oedema. Apparent diffusion coefficient
(ADC) and cerebral blood volume (CBV) maps were calculated and registered to T1
CE MRI. Differences between
ETP and PSP were evaluated using Mann-Whitney tests and p-values were adjusted
with Bonferroni correction. Logistic regressions with backward elimination
procedure and area under receiver operator characteristic curve (AUC) analyses
were used to assess the predictive ability of imaging parameters. Overall
survival (OS) were calculated from inclusion until death or last-follow-up.
Results
Based
on the trial recommendations and RANO criteria on new MRI one month after
progression suspicion, 28 patients were classified as PSP and 18 as ETP. After
a median follow up of 41 months, OS rate at 2 years was 60.7% in
PSP and 19.3% in ETP. Median survival was higher in PSP compared to ETP (25.2
months’ vs 20.3 months p=0.0092). There was no significant difference between
groups in terms of gender, arm of treatment, type of surgery and MGMT status. Higher
ratios of Lac/NAA and Cho/Cr were observed in ETP compared to those with PSP
(median respectively 1.2 vs 0.5, p=0.006 and 3 vs 2.2, p=0.021) within the CE
regions. ETP were characterized by Cho/Cr >2.33 with an AUC of 78%,
sensibility (se)83%, specificity (sp)64%. Other parameters were Lac/NAA
>0.61 and tumor volume (TV) >9.42 cc with respectively AUC of 81% and 81%,
se of 100% and 100%, and sp of 63 % and 61%. Within the FLAIR edema, no
significant predictor was retained after Bonferroni correction. TV was higher
in ETP than in PSP (23.2cc vs 7.2cc p= 0.0075). After multivariable regression
analysis, TV was the most significant predictor to classify ETP and PSP and the
only one retained in the model (p=0.028).
Conclusion
In
this analysis from a prospective trial including DWI, perfusion and MRSI, we
describe significant spectroscopic ratios, particularly surrogate’s markers of
hypoxia, i.e. lactate. TV remains the only predictive factor in the
multivariate analysis.
1. Laprie A et al, BMC
Cancer 2019